Neurogene vs Spruce Biosciences
NGNE and SPRB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NGNE and SPRB compare
Neurogene is the larger company, worth 3.9 times as much as Spruce Biosciences ($478M against $123M).
Neurogene scores higher on the StockData Score (7 against 3 for Spruce Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NGNE | SPRB |
|---|---|---|
| Size and price | ||
| Market cap | $478M | $123M |
| Share price | $23.90 | $42.89 |
| Change, 1 year | −22.6% | −61.9% |
| Change, 5 years | −77.5% | −80.5% |
| Beta (5Y) | 1.81 | – |
| Employees | 131 | 8 |
| StockData Score | ||
| Total score | 7 (better) | 3 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 1.3× (better) | 1.9× |
| FCF yield | −20.4% | – |
| Profitability | ||
| Return on equity | −38.4% (better) | −187% |
| Financial health | ||
| Debt / equity | 0.00 | 0.12 (better) |
| Interest coverage | −129924.0× | −21.3× (better) |
| Current ratio | 19.97 (better) | 4.83 |
| Altman Z-score | 10.72 (better) | −3.67 |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 86.5% | 69.7% |
| Held by insiders | 15.9% | 71.7% |
| Insider net buying, 12 months | −$1.1M | – |
| Short interest, % of float | 33.8% | 65.3% |
Go deeper
- NGNE stock overview
- NGNE income statement
- NGNE valuation and score
- SPRB stock overview
- SPRB income statement
- SPRB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.